ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2025
Randomized controlled trial of 4.0 mg versus 0.4 mg folic acid supplementation: Follow-up of children at 1 year of age.
Article in European journal of obstetrics & gynecology and reproductive biology: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Folic acid ameliorates placental structure and function in fetal growth restriction via epigenetic modifications.Clinical epigenetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective and study design: This 1-year follow-up study reports the results on the health status, visits to the paediatrician and hospitalizations of children born from the women recruited in the main randomized controlled trial (RCT) that investigated the effect of periconception folic acid (FA) supplementation of 4.0 mg/day on reducing adverse reproductive outcomes. Methods: The health status of livebirths was evaluated by a trained health care provider (HCP) through a phone interview with the paediatrician (at 1-3-12 months of age) and with the parents (at 12 months of age), using a structured data collection form. Results: Information at 1 year of life could be obtained for 347/376 (92.3 %) newborns included in the original RCT. No statistically significant differences were observed between the two groups regarding weight, health problems, hospitalizations from birth to 1 year of life and developmental milestones, as well as accesses to the emergency ward and parents'worries. Breastfeeding differed significantly at 1, 3 and 12 months of life, with higher proportion of exclusive breastfeeding in the 4.0 mg FA Group. Conclusion: The findings suggest that the periconception FA supplementation of 4.0 mg/day versus 0.4 mg/day, does not affect the health status and hospitalizations from birth to 1 year of life, as well as normal child's developmental milestones at 1 year of life. The increase in exclusive breastfeeding in the 4.0 mg FA group needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.